{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:52:21Z","timestamp":1793303541890,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2025A1515011241"],"award-info":[{"award-number":["2025A1515011241"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973183"],"award-info":[{"award-number":["81973183"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273762"],"award-info":[{"award-number":["82273762"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejmech.2025.118063","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T06:20:43Z","timestamp":1755498043000},"page":"118063","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Structure-based rational design of TLR7\/8 antagonists through agonist scaffold reengineering for psoriasis therapy"],"prefix":"10.1016","volume":"299","author":[{"given":"Peixi","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyue","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4620-8494","authenticated-orcid":false,"given":"Zhipeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118063_bib1","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.semcancer.2019.06.005","article-title":"Autoimmune diseases and hematological malignancies: exploring the underlying mechanisms from epidemiological evidence","volume":"64","author":"Hemminki","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejmech.2025.118063_bib2","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","article-title":"Pathogen recognition and innate immunity","volume":"124","author":"Akira","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.118063_bib3","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1146\/annurev-immunol-032414-112240","article-title":"Innate immune pattern recognition: a cell biological perspective","volume":"33","author":"Brubaker","year":"2015","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2025.118063_bib4","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3389\/fphar.2017.00460","article-title":"Drugs for autoimmune inflammatory diseases: from small molecule compounds to anti-TNF biologics","volume":"8","author":"Li","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118063_bib5","first-page":"428","article-title":"Calcitriol 3 microg\/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies","volume":"6","author":"Lebwohl","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ejmech.2025.118063_bib6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ajo.2025.05.002","article-title":"Efficacy and safety of biologics in pediatric noninfectious retinal vasculitis","volume":"277","author":"Karaca","year":"2025","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ejmech.2025.118063_bib7","article-title":"Janus kinase (JAK) inhibitor-induced acne in inflammatory bowel disease - an international, multicenter, retrospective cohort study","author":"Honap","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2025.118063_bib8","doi-asserted-by":"crossref","first-page":"4859","DOI":"10.1039\/c3cs60039d","article-title":"Targeting Toll-like receptors with small molecule agents","volume":"42","author":"Wang","year":"2013","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2025.118063_bib9","article-title":"Activated sympathetic nerve post stroke downregulates Toll-like receptor 5 and disrupts the gut mucosal barrier","volume":"5","author":"Wang","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ejmech.2025.118063_bib10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2174\/187152807783334300","article-title":"TLR7\/9 antagonists as therapeutics for immune-mediated inflammatory disorders","volume":"6","author":"Sun","year":"2007","journal-title":"Inflamm. Allergy - Drug Targets"},{"key":"10.1016\/j.ejmech.2025.118063_bib11","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.3390\/cells10061374","article-title":"Toll-like receptor signaling in the establishment and function of the immune system","volume":"10","author":"Aluri","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2025.118063_bib12","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1126\/science.1093620","article-title":"Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8","volume":"303","author":"Heil","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.118063_bib13","doi-asserted-by":"crossref","first-page":"5257","DOI":"10.1038\/s41467-019-13151-z","article-title":"The TLR7\/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer","volume":"10","author":"Michaelis","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118063_bib14","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1084\/jem.20050914","article-title":"Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus","volume":"202","author":"Barrat","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejmech.2025.118063_bib15","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/aps.2015.91","article-title":"Toll-like receptors: potential targets for lupus treatment","volume":"36","author":"Wu","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2025.118063_bib16","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jid.2022.10.017","article-title":"Cathelicidin antimicrobial peptide LL37 induces toll-like receptor 8 and amplifies IL-36\u03b3 and IL-17C in human keratinocytes","volume":"143","author":"Miura","year":"2023","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejmech.2025.118063_bib17","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/s12276-024-01225-y","article-title":"TLR7-dependent eosinophil degranulation links psoriatic skin inflammation to small intestinal inflammatory changes in mice","volume":"56","author":"Kim","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ejmech.2025.118063_bib18","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.3390\/molecules24112157","article-title":"Ameliorates imiquimod-induced psoriasis-like dermatitis and inhibits inflammatory cytokines production through TLR7\/8\u2013MyD88\u2013NF-\u03baB\u2013NLRP3 inflammasome pathway","volume":"24","author":"Yang","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118063_bib19","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1021\/acs.jmedchem.4c03148","article-title":"Discovery of novel isoxazole-based small-molecule toll-like receptor 8 antagonists","volume":"68","author":"Matziol","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118063_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004701","article-title":"Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first in patient, randomised, double-blind, phase I\/II study in systemic lupus erythematosus","volume":"10","author":"Tanaka","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.ejmech.2025.118063_bib21","article-title":"Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of afimetoran, a toll\u2010like receptor 7 and 8 inhibitor, in patients with cutaneous lupus erythematosus: a phase 1b randomized, double\u2010blind, placebo\u2010controlled study","volume":"7","author":"Hosein","year":"2025","journal-title":"ACR Open Rheumatol."},{"key":"10.1016\/j.ejmech.2025.118063_bib22","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1124\/jpet.120.000275","article-title":"Discovery of M5049: a novel selective toll-like receptor 7\/8 inhibitor for treatment of autoimmunity","volume":"376","author":"Vlach","year":"2021","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2025.118063_bib23","article-title":"Preclinical characterization of the Toll-like receptor 7\/8 antagonist MHV370 for lupus therapy","volume":"4","author":"Hawtin","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ejmech.2025.118063_bib24","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1038\/s41467-020-19025-z","article-title":"Structural analysis reveals TLR7 dynamics underlying antagonism","volume":"11","author":"Tojo","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118063_bib25","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1021\/acs.jmedchem.9b00411","article-title":"Novel and selective TLR7 antagonists among the imidazo[1,2-a]pyrazines, imidazo[1,5-a]quinoxalines, and pyrazolo[1,5-a]quinoxalines series","volume":"62","author":"Bou Karroum","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118063_bib26","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nchembio.2518","article-title":"Small-molecule inhibition of TLR8 through stabilization of its resting state","volume":"14","author":"Zhang","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118063_bib27","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.chembiol.2018.07.004","article-title":"Small-molecule TLR8 antagonists via structure-based rational design","volume":"25","author":"Hu","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118063_bib28","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1021\/jm100358c","article-title":"Structure\u2212Activity relationships in human toll-like receptor 7-active imidazoquinoline analogues","volume":"53","author":"Shukla","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118063_bib29","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1021\/acs.jmedchem.3c01504","article-title":"Heterocyclic-modified imidazoquinoline derivatives: selective TLR7 agonist regulates tumor microenvironment against melanoma","volume":"67","author":"Ou","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118063_bib30","doi-asserted-by":"crossref","first-page":"8346","DOI":"10.1021\/acs.jmedchem.4c00464","article-title":"Structure\u2013activity relationships toward the identification of a high-potency selective human toll-like receptor-7 agonist","volume":"67","author":"Kaushik","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118063_bib31","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.bmcl.2009.02.100","article-title":"Regioisomerism-dependent TLR7 agonism and antagonism in an imidazoquinoline","volume":"19","author":"Shukla","year":"2009","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2025.118063_bib32","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1021\/acs.jmedchem.0c00011","article-title":"A chemical switch for transforming a purine agonist for toll-like receptor 7 to a clinically relevant antagonist","volume":"63","author":"Mukherjee","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118063_bib33","doi-asserted-by":"crossref","first-page":"7955","DOI":"10.1021\/jm500744f","article-title":"Determinants of activity at human toll-like receptors 7 and 8: quantitative structure\u2013activity relationship (QSAR) of diverse heterocyclic scaffolds","volume":"57","author":"Yoo","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118063_bib34","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.immuni.2008.05.016","article-title":"Toll-like receptors activate innate and adaptive immunity by using dendritic cell-intrinsic and -extrinsic mechanisms","volume":"29","author":"Hou","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.ejmech.2025.118063_bib35","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/jid.2013.57","article-title":"A toll-like receptor 7, 8, and 9 antagonist inhibits Th1 and Th17 responses and inflammasome activation in a model of IL-23-induced psoriasis","volume":"133","author":"Jiang","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejmech.2025.118063_bib36","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","article-title":"Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 Axis","volume":"182","author":"van der Fits","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2025.118063_bib37","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1021\/acs.jmedchem.1c02058","article-title":"Discovery and structural optimization of toddacoumalone derivatives as novel PDE4 inhibitors for the topical treatment of psoriasis","volume":"65","author":"Song","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118063_bib38","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2025.118063_bib39","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.118063_bib40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2478\/sjdv-2020-0006","article-title":"Evaluation of IHC Ki-67 with clinical correlation in psoriasis","volume":"12","author":"Borade","year":"2020","journal-title":"Serbian J. Dermatol. Venereol."},{"key":"10.1016\/j.ejmech.2025.118063_bib41","doi-asserted-by":"crossref","first-page":"7371","DOI":"10.1021\/acs.jmedchem.0c02266","article-title":"Design, synthesis, and structure\u2013activity relationship of N-Aryl-N\u2032-(thiophen-2-yl)thiourea derivatives as novel and specific human TLR1\/2 agonists for potential cancer immunotherapy","volume":"64","author":"Chen","year":"2021","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425008281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425008281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T12:59:59Z","timestamp":1772801999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425008281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":41,"alternative-id":["S0223523425008281"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118063","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-based rational design of TLR7\/8 antagonists through agonist scaffold reengineering for psoriasis therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118063"}}